Armata Pharmaceuticals Inc (ARMP) Stock Price, Quote & News

Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 665 2928

Fax: 310 665 2963

Website: www.armatapharma.com

Address:

5005 McConnell Avenue, Los Angeles, United States

Iightning Dec. 5 at 12:22 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ARMP Contract: Dec 19 $2.5C Entry: 3.05 Exit: 4.59 Return: +50.50% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Kingcrab33333 Dec. 4 at 6:15 PM

$ARMP ( load)

0 · Reply

HexBinance Dec. 4 at 5:23 PM

$CLSK I have the self-awareness to understand that I'm probably most likely talking to no one other than myself here but if I gained any faith with $ARMP ( stay in there and put more in when you're comfortable) please let me Direct some of your attention over to $RCEL. I'm not a wizard I don't know the future, but I take my time and I only invest in things I have 100% concrete evidence of. Long term very valuable short-term it's a steal.

0 · Reply

Iightning Dec. 4 at 8:01 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ARMP Contract: Dec 19 $2.5C Entry: 3.50 Exit: 5.71 Return: +63.12% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

HexBinance Dec. 3 at 10:22 PM

$CLSK $ARMP went from -20% EOD yesterday to +12% EOD today, and for you young whipper snappers that's called a Bullish Shakeout. It happens on smallcap rocketships as an attempt to shakeout you paper hands who still believe stop-losses are there to help you. Time to wake up, Hunnie, because the bad guys have been winning for too long. Same old story, weak hands were flushed out and the knowing swooped in and gobbled up free money. If it was a reversal it n wouldn't have snapped back with such strength today. The money is still in charge. I gave it to you without expecting anything in return simply because if you're on team Matt & Zach then I want us all to do well together.

2 · Reply

HexBinance Dec. 3 at 3:20 PM

$CLSK in case you guys thought I was just another one of these jerk off tights trying to steal your money let me remind you that I told you about $ARMP yesterday when it was down 20%

0 · Reply

prallrichard Dec. 3 at 2:02 PM

$ARMP Offerings happen! Even from the best!

0 · Reply

Alex036 Dec. 3 at 12:34 PM

$ARMP they just secured funding for the puppeteer's deep pocket

0 · Reply

Trapped Dec. 2 at 8:48 PM

$ARMP they secured funding for the pipeline of drugs coming up the road.

0 · Reply

prallrichard Dec. 2 at 8:24 PM

$ARMP Form 424B5 is a supplemental prospectus filed with the SEC to update or correct information in a previously filed prospectus, often used in shelf offerings to add specific details about a particular security being offered. It combines information typically covered by both Rule 424(b)(2) (for prospectus supplements with omitted information) and Rule 424(b)(3) (for substantive changes to previously filed information). This allows companies to provide detailed, up-to-date information to investors about a specific offering without needing to file a completely new registration statement. No big deal for longs!

0 · Reply

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

Nov 12, 2025, 4:05 PM EST - 22 days ago

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

Nov 10, 2025, 7:00 AM EST - 24 days ago

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

Oct 22, 2025, 11:10 AM EDT - 6 weeks ago

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

Oct 14, 2025, 7:00 AM EDT - 7 weeks ago

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

Sep 8, 2025, 7:00 AM EDT - 3 months ago

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Sep 4, 2025, 7:00 AM EDT - 3 months ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

May 19, 2025, 7:00 AM EDT - 7 months ago

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

May 14, 2025, 4:05 PM EDT - 7 months ago

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

May 1, 2025, 7:00 AM EDT - 7 months ago

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Mar 20, 2025, 5:56 PM EDT - 9 months ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Mar 12, 2025, 5:08 PM EDT - 9 months ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

INVA

Mar 11, 2025, 7:00 AM EDT - 9 months ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Dec 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Nov 13, 2024, 4:05 PM EST - 1 year ago

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Nov 12, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Structural Biology Publication

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Aug 15, 2024, 4:45 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Jul 10, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

May 7, 2024, 4:01 PM EDT - 1 year ago

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Mar 4, 2024, 4:01 PM EST - 1 year ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

INVA

Feb 21, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Nov 14, 2023, 4:00 PM EST - 2 years ago

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

May 31, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

May 11, 2023, 4:05 PM EDT - 2 years ago

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

Mar 16, 2023, 4:10 PM EDT - 2 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

Mar 6, 2023, 6:00 AM EST - 2 years ago

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Jan 10, 2023, 4:05 PM EST - 3 years ago

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

INVA

Dec 22, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 28, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Nov 9, 2022, 4:15 PM EST - 3 years ago

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

May 23, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

May 12, 2022, 4:17 PM EDT - 3 years ago

Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update

Mar 31, 2022, 4:05 PM EDT - 4 years ago

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva

INVA

Mar 17, 2022, 4:05 PM EDT - 4 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update

Iightning Dec. 5 at 12:22 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ARMP Contract: Dec 19 $2.5C Entry: 3.05 Exit: 4.59 Return: +50.50% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Kingcrab33333 Dec. 4 at 6:15 PM

$ARMP ( load)

0 · Reply

HexBinance Dec. 4 at 5:23 PM

0 · Reply

Iightning Dec. 4 at 8:01 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ARMP Contract: Dec 19 $2.5C Entry: 3.50 Exit: 5.71 Return: +63.12% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

HexBinance Dec. 3 at 10:22 PM

2 · Reply

HexBinance Dec. 3 at 3:20 PM

$CLSK in case you guys thought I was just another one of these jerk off tights trying to steal your money let me remind you that I told you about $ARMP yesterday when it was down 20%

0 · Reply

prallrichard Dec. 3 at 2:02 PM

$ARMP Offerings happen! Even from the best!

0 · Reply

Alex036 Dec. 3 at 12:34 PM

$ARMP they just secured funding for the puppeteer's deep pocket

0 · Reply

Trapped Dec. 2 at 8:48 PM

$ARMP they secured funding for the pipeline of drugs coming up the road.

0 · Reply

prallrichard Dec. 2 at 8:24 PM

0 · Reply

HexBinance Dec. 2 at 7:38 PM

$CLSK 👁👁 $ARMP 👀down -20% today. Do your own DD, but if you're too lazy- it's not a meme, it's got terrific long term potential.

0 · Reply

Trapped Dec. 2 at 4:24 PM

$ARMP arrrruuuuuggggaaaaaa!!! cheap shares available!!!!

0 · Reply

HexBinance Dec. 2 at 2:51 PM

$CLSK friends, remember to always think for yourself and question any and every authority. That said- $ARMP VERY interesting movement from a company that I like very much. I wish it would hold on until after the new year, but these thing's rarely happen on *my* terms.

0 · Reply

Iightning Dec. 2 at 2:32 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $ARMP **Contract:** Dec 19 $7.5C **Entry:** 2.28 **Exit:** 3.42 **Return:** **+50.12% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Kingcrab33333 Dec. 1 at 9:05 PM

$ARMP

0 · Reply

Trapped Nov. 29 at 1:12 PM

$ARMP this baby going to $50. phase 3 trials coming.

0 · Reply

prallrichard Nov. 28 at 8:48 PM

$ARMP ARMP appears to be correcting within a longer-term bullish trend. Although its MACD is presently below the signal line, shares remain 168.3% above an upwards sloping 200-day moving average. Comparative Relative Strength analysis shows that this issue is outperforming the S&P 500.

0 · Reply

prallrichard Nov. 28 at 2:35 AM

$ARMP Momentum for ARMP is strongly bullish. The 14-period Slow Stochastic oscillator is above 80, the level which many analysts call overbought.

0 · Reply

Iightning Nov. 26 at 5:29 AM

1ightning® Options Trade Alert (Actionable) | Buy $ARMP Dec 19 $8 Call | Enter: $2.28 Exit: $2.97 | Profit: 30.42% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 3:37 PM

1ightning® Options Trade Alert (Actionable) | Buy $ARMP Dec 19 $8 Call | Enter: $2.28 Exit: $2.97 | Profit: 30.42% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:31 AM

1ightning® Options Trade Alert (Actionable) | Buy $ARMP Dec 19 $8 Call | Enter: $2.28 Exit: $2.97 | Profit: 30.42% ROI | https://1ightning.com

0 · Reply

Kingcrab33333 Nov. 24 at 9:18 PM

$ARMP

0 · Reply

Market Cap	192.91M
Revenue (ttm)	5.17M
Net Income (ttm)	-18.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-365.96%
Debt to Equity Ratio	-1.53

Volume	69,700
Avg Vol	346,804
Day's Range	N/A - N/A
Shares Out	36.33M
Stochastic %K	35%
Beta	1.24
Analysts	Sell
Price Target	$9.00